ARYX (ARYx Therapeutics) Debt-to-Asset : 2.06 (As of Sep. 2010)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ARYx Therapeutics Debt-to-Asset?

ARYx Therapeutics ARYX -99.80% Debt-to-Asset is 2.06 as of Sep. 2010.

ARYx Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2010 was $6.83 Mil. ARYx Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2010 was $5.50 Mil. ARYx Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2010 was $5.97 Mil. ARYx Therapeutics's debt to asset for the quarter that ended in Sep. 2010 was 2.06.

ARYx Therapeutics  (OTCPK:ARYX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ARYx Therapeutics Debt-to-Asset Related Terms

ARYx Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for ARYx Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARYx Therapeutics Debt-to-Asset Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Debt-to-Asset
Get a 7-Day Free Trial 0.34 0.17 0.10 0.32 0.95

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.95 0.90 1.54 2.06

ARYX vs YBAO, HPMM, BKIT: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARYx Therapeutics Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Debt-to-Asset falls into.


ARYx Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ARYx Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2009 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.183 + 6.641) / 12.406
=0.95

ARYx Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2010 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.825 + 5.495) / 5.972
=2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 2.06 mean?
ARYx Therapeutics (ARYX) has a Debt-to-Asset of 2.06 as of Sep. 2010. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on ARYx Therapeutics and its competitors.
Is ARYx Therapeutics' Debt-to-Asset too high?
ARYx Therapeutics' current Debt-to-Asset is 2.06.
How does ARYx Therapeutics' Debt-to-Asset compare to YBAO and HPMM?
ARYx Therapeutics' Debt-to-Asset of 2.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on ARYx Therapeutics and its competitors. ARYx Therapeutics's current Debt-to-Asset is 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARYx Therapeutics stock overvalued right now?
ARYx Therapeutics (ARYX) has a current Debt-to-Asset of 2.06. The current Debt-to-Asset is 2.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For ARYx Therapeutics (ARYX), the current Debt-to-Asset is 2.06 as of Sep. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARYx Therapeutics Business Description

Address 6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.